List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10958071/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer. European Journal of Cancer, 2022, 160, 100-111.	2.8	12
2	Rare germline copy number variants (CNVs) and breast cancer risk. Communications Biology, 2022, 5, 65.	4.4	6
3	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	2.8	23
4	Common variants in breast cancer risk loci predispose to distinct tumor subtypes. Breast Cancer Research, 2022, 24, 2.	5.0	15
5	ABC6 Consensus: Assessment by a Group of German Experts. Breast Care, 2022, 17, 90-100.	1.4	6
6	Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes. JAMA Oncology, 2022, 8, e216744.	7.1	51
7	OUP accepted manuscript. Human Molecular Genetics, 2022, , .	2.9	1
8	Update Breast Cancer 2021 Part 4 – Prevention and Early Stages. Geburtshilfe Und Frauenheilkunde, 2022, 82, 206-214.	1.8	4
9	Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. New England Journal of Medicine, 2022, 386, 556-567.	27.0	444
10	Update Breast Cancer 2021 Part 5 – Advanced Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2022, 82, 215-225.	1.8	6
11	Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2â^' Advanced Breast Cancer in the MONALEESA-3 Trial. Clinical Breast Cancer, 2022, 22, 326-335.	2.4	2
12	The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer—a pooled analysis of the randomised clinical trials PlanB and SUCCESS C. British Journal of Cancer, 2022, 126, 1715-1724.	6.4	14
13	Genome-wide and transcriptome-wide association studies of mammographic density phenotypes reveal novel loci. Breast Cancer Research, 2022, 24, 27.	5.0	15
14	Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer. JAMA Oncology, 2022, , .	7.1	7
15	Breast cancer risks associated with missense variants in breast cancer susceptibility genes. Genome Medicine, 2022, 14, 51.	8.2	19
16	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 217-228.	2.5	12
17	Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk. Journal of the National Cancer Institute, 2021, 113, 329-337.	6.3	45
18	Influence of Family History of Breast or Ovarian Cancer on Pathological Complete Response and Long-Term Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Breast Care, 2021, 16, 254-262.	1.4	0

#	Article	IF	CITATIONS
19	Genetic variations in estrogen and progesterone pathway genes in preeclampsia patients and controls in Bavaria. Archives of Gynecology and Obstetrics, 2021, 303, 897-904.	1.7	2
20	CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. British Journal of Cancer, 2021, 124, 842-854.	6.4	5
21	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature Communications, 2021, 12, 1078.	12.8	19
22	Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer. Clinical Cancer Research, 2021, 27, 2584-2591.	7.0	27
23	Breast Cancer Risk Genes — Association Analysis in More than 113,000 Women. New England Journal of Medicine, 2021, 384, 428-439.	27.0	532
24	Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy. European Journal of Cancer, 2021, 145, 44-52.	2.8	5
25	Update Breast Cancer 2020 Part 5 – Moving Therapies From Advanced to Early Breast Cancer Patients. Geburtshilfe Und Frauenheilkunde, 2021, 81, 469-480.	1.8	6
26	Gene-Environment Interactions Relevant to Estrogen and Risk of Breast Cancer: Can Gene-Environment Interactions Be Detected Only among Candidate SNPs from Genome-Wide Association Studies?. Cancers, 2021, 13, 2370.	3.7	4
27	Mutations in <i>BRCA1/2</i> and Other Panel Genes in Patients With Metastatic Breast Cancer —Association With Patient and Disease Characteristics and Effect on Prognosis. Journal of Clinical Oncology, 2021, 39, 1619-1630.	1.6	39
28	Update Breast Cancer 2021 Part 2 – Advanced Stages, Long-Term Consequences and Biomarkers. Geburtshilfe Und Frauenheilkunde, 2021, 81, 539-548.	1.8	6
29	Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus. Geburtshilfe Und Frauenheilkunde, 2021, 81, 637-653.	1.8	5
30	Update Breast Cancer 2021 Part 1 – Prevention and Early Stages. Geburtshilfe Und Frauenheilkunde, 2021, 81, 526-538.	1.8	10
31	Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors – An analysis of 2765 patients from neoadjuvant clinical trials. European Journal of Cancer, 2021, 148, 159-170.	2.8	41
32	Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy. , 2021, 9, e002605.		7
33	Identification of a Locus Near <i>ULK1</i> Associated With Progression-Free Survival in Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1669-1680.	2.5	5
34	Update Breast Cancer 2021 Part 3 – Current Developments in the Treatment of Early Breast Cancer: Review and Assessment of Specialised Treatment Scenarios by an International Expert Panel. Geburtshilfe Und Frauenheilkunde, 2021, 81, 654-665.	1.8	4
35	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. American Journal of Human Genetics, 2021, 108, 1190-1203.	6.2	6
36	Genetic analyses of gynecological disease identify genetic relationships between uterine fibroids and endometrial cancer, and a novel endometrial cancer genetic risk region at the WNT4 1p36.12 locus. Human Genetics, 2021, 140, 1353-1365.	3.8	18

#	Article	IF	CITATIONS
37	Utility of the CPSÂ+ÂEG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy. European Journal of Cancer, 2021, 153, 203-212.	2.8	8
38	Comparison of methods for isolation and quantification of circulating cell-free DNA from patients with endometriosis. Reproductive BioMedicine Online, 2021, 43, 788-798.	2.4	2
39	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. Breast Cancer Research, 2021, 23, 86.	5.0	7
40	Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncology, The, 2021, 22, 1151-1161.	10.7	248
41	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. British Journal of Cancer, 2021, 125, 1135-1145.	6.4	9
42	Genetic insights into biological mechanisms governing human ovarian ageing. Nature, 2021, 596, 393-397.	27.8	183
43	AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021. Breast Care, 2021, 16, 228-235.	1.4	20
44	AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021. Breast Care, 2021, 16, 214-227.	1.4	51
45	Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis. Scientific Reports, 2021, 11, 19787.	3.3	2
46	Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes. Cancers, 2021, 13, 5577.	3.7	5
47	Update Mammakarzinom 2021 Teil 1 – Präention und frühe Krankheitsstadien. Senologie - Zeitschrift Fżr Mammadiagnostik Und -therapie, 2021, 18, 377-390.	0.0	0
48	Detection of ESR1 Mutations in Single Circulating Tumor Cells on Estrogen Deprivation Therapy but Not in Primary Tumors from Metastatic Luminal Breast Cancer Patients. Journal of Molecular Diagnostics, 2020, 22, 111-121.	2.8	22
49	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	21.4	120
50	Concerning Dediu M, Zielinski A: A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer. Breast Care 2019; Doi 10.1159/000500620. Breast Care, 2020, 15, 96-101.	1.4	1
51	Risk of postmenopausal hormone therapy and patient history factors for the survival rate in women with endometrial carcinoma. Archives of Gynecology and Obstetrics, 2020, 301, 289-294.	1.7	5
52	Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. New England Journal of Medicine, 2020, 382, 514-524.	27.0	482
53	Gene Expression Signatures of BRCAness and Tumor Inflammation Define Subgroups of Early-Stage Hormone Receptor–Positive Breast Cancer Patients. Clinical Cancer Research, 2020, 26, 6523-6534. 	7.0	16
54	HLA-G and HLA-F protein isoform expression in breast cancer patients receiving neoadjuvant treatment. Scientific Reports, 2020, 10, 15750.	3.3	15

#	Article	IF	CITATIONS
55	Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study. Breast, 2020, 54, 148-154.	2.2	25
56	Update Breast Cancer 2020 Part 3 – Early Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2020, 80, 1105-1114.	1.8	12
57	Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC. , 2020, 8, e001261.		18
58	Update Breast Cancer 2020 Part 4 – Advanced Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2020, 80, 1115-1122.	1.8	11
59	HLA-J, a Non-Pseudogene as a New Prognostic Marker for Therapy Response and Survival in Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2020, 80, 1123-1133.	1.8	13
60	Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine. Geburtshilfe Und Frauenheilkunde, 2020, 80, 1134-1142.	1.8	4
61	Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany. BMC Cancer, 2020, 20, 1091.	2.6	1
62	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. American Journal of Human Genetics, 2020, 107, 837-848.	6.2	39
63	Impact of fibroblast growth factor receptor 1 (FGFR1) amplification on the prognosis of breast cancer patients. Breast Cancer Research and Treatment, 2020, 184, 311-324.	2.5	10
64	Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis. Cancer Research, 2020, 80, 5427-5434.	0.9	77
65	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	21.4	265
66	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. Scientific Reports, 2020, 10, 9688.	3.3	2
67	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). Clinical Cancer Research, 2020, 26, 5411-5423.	7.0	43
68	Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. British Journal of Cancer, 2020, 123, 793-802.	6.4	35
69	Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer. JAMA Oncology, 2020, 6, 744.	7.1	42
70	Update Breast Cancer 2020 Part 1 – Early Breast Cancer: Consolidation of Knowledge About Known Therapies. Geburtshilfe Und Frauenheilkunde, 2020, 80, 277-287.	1.8	16
71	Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials. European Journal of Cancer, 2020, 130, 92-101.	2.8	26
72	Pembrolizumab for Early Triple-Negative Breast Cancer. New England Journal of Medicine, 2020, 382, 810-821.	27.0	1,542

#	Article	IF	CITATIONS
73	Transcriptomeâ€wide association study of breast cancer risk by estrogenâ€receptor status. Genetic Epidemiology, 2020, 44, 442-468.	1.3	32
74	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. Nature Communications, 2020, 11, 312.	12.8	30
75	Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts. Breast Cancer Research and Treatment, 2020, 181, 423-434.	2.5	14
76	Update Breast Cancer 2020 Part 2 – Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics. Geburtshilfe Und Frauenheilkunde, 2020, 80, 391-398.	1.8	12
77	Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1096-1104.	4.9	33
78	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. Cancer Research, 2019, 79, 505-517.	0.9	49
79	Characterization of Molecular Subtypes of Paget Disease of the Breast Using Immunohistochemistry and In Situ Hybridization. Archives of Pathology and Laboratory Medicine, 2019, 143, 206-211.	2.5	18
80	Genetic predictors of chemotherapy-related amenorrhea inÂwomen with breast cancer. Fertility and Sterility, 2019, 112, 731-739.e1.	1.0	10
81	The genetic interplay between body mass index, breast size and breast cancer risk: a Mendelian randomization analysis. International Journal of Epidemiology, 2019, 48, 781-794.	1.9	37
82	Fatal events during clinical trials: an evaluation of deaths during breast cancer studies. Breast Cancer, 2019, 26, 826-834.	2.9	0
83	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. Npj Breast Cancer, 2019, 5, 38.	5.2	28
84	Update Breast Cancer 2019 Part 4 – Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2019, 79, 1079-1089.	1.8	18
85	Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy – German Experts' Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019). Breast Care, 2019, 14, 315-324.	1.4	9
86	Two truncating variants in FANCC and breast cancer risk. Scientific Reports, 2019, 9, 12524.	3.3	5
87	AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019. Breast Care, 2019, 14, 224-245.	1.4	72
88	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	12.8	88
89	Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial. International Journal of Cancer, 2019, 145, 857-868.	5.1	12
90	A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). Clinical Cancer Research, 2019, 25, 2975-2987.	7.0	76

#	Article	IF	CITATIONS
91	Joint association of mammographic density adjusted for age and body mass index and polygenic risk score with breast cancer risk. Breast Cancer Research, 2019, 21, 68.	5.0	31
92	Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus. Geburtshilfe Und Frauenheilkunde, 2019, 79, 591-604.	1.8	20
93	Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) – Recommendations for Daily Routine Practice. Geburtshilfe Und Frauenheilkunde, 2019, 79, 605-617.	1.8	28
94	Update Breast Cancer 2019 Part 1 – Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2019, 79, 256-267.	1.8	17
95	Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. Journal of Clinical Oncology, 2019, 37, 2206-2216.	1.6	152
96	Update Breast Cancer 2019 Part 3 – Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel. Geburtshilfe Und Frauenheilkunde, 2019, 79, 470-482.	1.8	26
97	Update Breast Cancer 2019 Part 2 – Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice. Geburtshilfe Und Frauenheilkunde, 2019, 79, 268-280.	1.8	21
98	Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto. Breast Cancer Research, 2019, 21, 60.	5.0	16
99	NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69–GeparSepto. Journal of Clinical Oncology, 2019, 37, 2226-2234.	1.6	95
100	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741.	12.8	90
101	Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer. Breast Cancer Research and Treatment, 2019, 175, 617-625.	2.5	35
102	Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial. Clinical Cancer Research, 2019, 25, 3986-3995.	7.0	32
103	Genome-wide association study of germline variants and breast cancer-specific mortality. British Journal of Cancer, 2019, 120, 647-657.	6.4	52
104	Translational highlights in breast cancer research and treatment: recent developments with clinical impact. Current Opinion in Obstetrics and Gynecology, 2019, 31, 67-75.	2.0	16
105	Neoadjuvant Treatment of HER2-Positive Breast Cancer—A Review. , 2019, , 95-106.		0
106	Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial. British Journal of Cancer, 2019, 121, 1009-1015.	6.4	12
107	Prediction and clinical utility of a contralateral breast cancer risk model. Breast Cancer Research, 2019, 21, 144.	5.0	24
108	Translational Highlights in Breast and Ovarian Cancer 2019 – Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy. Geburtshilfe Und Frauenheilkunde, 2019, 79, 1309-1319.	1.8	11

#	Article	IF	CITATIONS
109	Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy. Breast Cancer Research, 2019, 21, 142.	5.0	21
110	Awareness of breast cancer incidence and risk factors among healthy women in Germany: an update after 10 years. European Journal of Cancer Prevention, 2019, 28, 515-521.	1.3	12
111	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics, 2019, 104, 21-34.	6.2	711
112	Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer. Breast Cancer Research and Treatment, 2019, 174, 453-461.	2.5	15
113	Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis. Breast Cancer Research and Treatment, 2019, 173, 319-328.	2.5	40
114	Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. New England Journal of Medicine, 2019, 380, 617-628.	27.0	1,610
115	Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis. Journal of the National Cancer Institute, 2019, 111, 380-387.	6.3	101
116	Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. International Journal of Epidemiology, 2019, 48, 795-806.	1.9	81
117	The <i>BRCA2</i> c.68-7TÂ>ÂA variant is not pathogenic: A model for clinical calibration of spliceogenicity. Human Mutation, 2018, 39, 729-741.	2.5	19
118	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clinic Proceedings, 2018, 93, 307-320.	3.0	22
119	TILGen: A Program to Investigate Immune Targets in Breast Cancer Patients - First Results on the Influence of Tumor-Infiltrating Lymphocytes. Breast Care, 2018, 13, 8-14.	1.4	32
120	Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study. Oncology Research and Treatment, 2018, 41, 93-98.	1.2	8
121	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. British Journal of Cancer, 2018, 118, 1123-1129.	6.4	15
122	Genetic overlap between endometriosis and endometrial cancer: evidence from crossâ€disease genetic correlation and GWAS metaâ€analyses. Cancer Medicine, 2018, 7, 1978-1987.	2.8	62
123	Update Breast Cancer 2018 (Part 1) – Primary Breast Cancer and Biomarkers. Geburtshilfe Und Frauenheilkunde, 2018, 78, 237-245.	1.8	20
124	Joint associations of a polygenic risk score and environmental risk factors for breast cancer in the Breast Cancer Association Consortium. International Journal of Epidemiology, 2018, 47, 526-536.	1.9	88
125	Breast cancer in young women: do BRCA1 or BRCA2 mutations matter?. Lancet Oncology, The, 2018, 19, 150-151.	10.7	12
126	Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients. BMC Cancer, 2018, 18, 204.	2.6	30

#	Article	IF	CITATIONS
127	BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients. Breast Cancer Research and Treatment, 2018, 171, 85-94.	2.5	56
128	Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2018, 47, 450-459.	1.9	15
129	Update Breast Cancer 2018 (Part 2) – Advanced Breast Cancer, Quality of Life and Prevention. Geburtshilfe Und Frauenheilkunde, 2018, 78, 246-259.	1.8	23
130	Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. Breast Cancer Research and Treatment, 2018, 167, 59-71.	2.5	32
131	Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncology, The, 2018, 19, 40-50.	10.7	1,327
132	Outcome after neoadjuvant chemotherapy in elderly breast cancer patients - a pooled analysis of individual patient data from eight prospectively randomized controlled trials. Oncotarget, 2018, 9, 15168-15179.	1.8	29
133	BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. Journal of Clinical Oncology, 2018, 36, 2281-2287.	1.6	86
134	Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3. Journal of Clinical Oncology, 2018, 36, 2465-2472.	1.6	704
135	Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44). Journal of Clinical Oncology, 2018, 36, 1308-1316.	1.6	43
136	Update Breast Cancer 2018 (Part 4) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2018, 78, 1119-1128.	1.8	3
137	Update Breast Cancer 2018 (Part 3) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2018, 78, 1110-1118.	1.8	8
138	Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. BMC Medicine, 2018, 16, 179.	5.5	134
139	Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer. BMC Cancer, 2018, 18, 1051.	2.6	59
140	Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2018, 78, 927-948.	1.8	59
141	Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab. Pharmacogenetics and Genomics, 2018, 28, 147-152.	1.5	4
142	The effect of participation in neoadjuvant clinical trials on outcomes in patients with early breast cancer. Breast Cancer Research and Treatment, 2018, 171, 747-758.	2.5	12
143	Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. Journal of Pathology: Clinical Research, 2018, 4, 250-261.	3.0	70
144	MicroRNA in diagnosis and therapy monitoring of early-stage triple-negative breast cancer. Scientific Reports, 2018, 8, 11584.	3.3	91

#	Article	IF	CITATIONS
145	Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing. Journal of the National Cancer Institute, 2018, 110, 855-862.	6.3	225
146	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Research, 2018, 78, 5419-5430.	0.9	54
147	Self-reported Improvement in Side Effects and Quality of Life With Integrative Medicine in Breast Cancer Patients. Integrative Cancer Therapies, 2018, 17, 941-951.	2.0	9
148	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLoS ONE, 2018, 13, e0197561.	2.5	9
149	Identification of nine new susceptibility loci for endometrial cancer. Nature Communications, 2018, 9, 3166.	12.8	178
150	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. International Journal of Molecular Sciences, 2018, 19, 2473.	4.1	3
151	Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients – a Survey Among Physicians. Geburtshilfe Und Frauenheilkunde, 2018, 78, 707-714.	1.8	3
152	Risk, Prediction and Prevention of Hereditary Breast Cancer – Large-Scale Genomic Studies in Times of Big and Smart Data. Geburtshilfe Und Frauenheilkunde, 2018, 78, 481-492.	1.8	38
153	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nature Genetics, 2018, 50, 968-978.	21.4	184
154	Prevalence of circulating tumor cells in early breast cancer patients 2 and 5Âyears after adjuvant treatment. Breast Cancer Research and Treatment, 2018, 171, 571-580.	2.5	12
155	Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. British Journal of Cancer, 2017, 116, 524-535.	6.4	23
156	Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer. Clinical Breast Cancer, 2017, 17, 279-285.	2.4	10
157	Genetic risk factors for ovarian cancer and their role for endometriosis risk. Gynecologic Oncology, 2017, 145, 142-147.	1.4	24
158	<i>BRCA2</i> Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. Cancer Research, 2017, 77, 2789-2799.	0.9	75
159	Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk. Nature Genetics, 2017, 49, 834-841.	21.4	426
160	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
161	Dose-Response Association of CD8 ⁺ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncology, 2017, 3, e173290.	7.1	260
162	Association analysis identifies 65 new breast cancer risk loci. Nature, 2017, 551, 92-94.	27.8	1,099

#	Article	IF	CITATIONS
163	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	21.4	289
164	Gene–environment interactions involving functional variants: Results from the Breast Cancer Association Consortium. International Journal of Cancer, 2017, 141, 1830-1840.	5.1	20
165	Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer. JAMA Oncology, 2017, 3, 1378.	7.1	300
166	Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). European Journal of Cancer, 2017, 84, 1-8.	2.8	13
167	Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus. Geburtshilfe Und Frauenheilkunde, 2017, 77, 633-644.	1.8	28
168	Germline variation in ADAMTSL1 is associated with prognosis following breast cancer treatment in young women. Nature Communications, 2017, 8, 1632.	12.8	18
169	Predicting Triple-Negative Breast Cancer Subtype Using Multiple Single Nucleotide Polymorphisms for Breast Cancer Risk and Several Variable Selection Methods. Geburtshilfe Und Frauenheilkunde, 2017, 77, 667-678.	1.8	21
170	Genetic modifiers of CHEK2*1100delC-associated breast cancer risk. Genetics in Medicine, 2017, 19, 599-603.	2.4	67
171	Interest in Integrative Medicine Among Postmenopausal Hormone Receptor–Positive Breast Cancer Patients in the EvAluate-TM Study. Integrative Cancer Therapies, 2017, 16, 165-175.	2.0	22
172	Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer. Scientific Reports, 2017, 7, 17307.	3.3	16
173	Update Breast Cancer 2017 – Implementation of Novel Therapies. Geburtshilfe Und Frauenheilkunde, 2017, 77, 1281-1290.	1.8	19
174	Circulating Tumour Cells, Circulating Tumour DNA and Circulating MicroRNA in Metastatic Breast Carcinoma – What is the Role of Liquid Biopsy in Breast Cancer?. Geburtshilfe Und Frauenheilkunde, 2017, 77, 1291-1298.	1.8	18
175	Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer. JCO Precision Oncology, 2017, 1, 1-12.	3.0	9
176	Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study. Breast Cancer Research, 2017, 19, 119.	5.0	43
177	TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer. Oncotarget, 2017, 8, 18381-18398.	1.8	14
178	Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. Oncotarget, 2017, 8, 64670-64684.	1.8	7
179	<i>PHIP</i> a novel candidate breast cancer susceptibility locus on 6q14.1. Oncotarget, 2017, 8, 102769-102782.	1.8	9
180	Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. Oncotarget, 2016, 7, 80140-80163.	1.8	31

#	Article	IF	CITATIONS
181	Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent. PLoS Medicine, 2016, 13, e1002105.	8.4	118
182	Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. PLoS ONE, 2016, 11, e0160316.	2.5	12
183	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 884-895.	1.9	71
184	Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer – Results of the German SUCCESS-A- trial. BMC Cancer, 2016, 16, 401.	2.6	14
185	Fineâ€scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. International Journal of Cancer, 2016, 139, 1303-1317.	5.1	51
186	Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Modern Pathology, 2016, 29, 1155-1164.	5.5	230
187	<i>PALB2</i> , <i>CHEK2</i> and <i>ATM</i> rare variants and cancer risk: data from COCS. Journal of Medical Genetics, 2016, 53, 800-811.	3.2	174
188	Neoadjuvant Treatment of Breast Cancer - Advances and Limitations. Breast Care, 2016, 11, 313-314.	1.4	12
189	Patient survival and tumor characteristics associated with CHEK2:p.I157T – findings from the Breast Cancer Association Consortium. Breast Cancer Research, 2016, 18, 98.	5.0	39
190	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research, 2016, 18, 64.	5.0	31
191	Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study. Breast Care, 2016, 11, 315-322.	1.4	6
192	Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer. Clinical Cancer Research, 2016, 22, 5747-5754.	7.0	158
193	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Human Genetics, 2016, 135, 741-756.	3.8	19
194	Genetic predisposition to ductal carcinoma in situ of the breast. Breast Cancer Research, 2016, 18, 22.	5.0	43
195	Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. Cancer Causes and Control, 2016, 27, 679-693.	1.8	21
196	Five endometrial cancer risk loci identified through genome-wide association analysis. Nature Genetics, 2016, 48, 667-674.	21.4	77
197	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 1619-1630.	1.9	111
198	Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation. American Journal of Human Genetics, 2016, 99, 903-911.	6.2	59

#	Article	IF	CITATIONS
199	An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. Human Molecular Genetics, 2016, 25, 3863-3876.	2.9	33
200	Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist:Hip Ratio, Is Causal for Endometrial Cancer. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1503-1510.	2.5	64
201	rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk. Scientific Reports, 2016, 6, 36874.	3.3	2
202	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	9.4	157
203	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	12.8	93
204	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	12.8	78
205	Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). Scientific Reports, 2016, 6, 32512.	3.3	19
206	Going Digital: A Survey on Digitalization and Large-Scale Data Analytics in Healthcare. Proceedings of the IEEE, 2016, 104, 2180-2206.	21.3	89
207	Age- and Tumor Subtype–Specific Breast Cancer Risk Estimates for <i>CHEK2</i> *1100delC Carriers. Journal of Clinical Oncology, 2016, 34, 2750-2760.	1.6	152
208	Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer. Clinical Cancer Research, 2016, 22, 2675-2683.	7.0	41
209	CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer. Endocrine-Related Cancer, 2016, 23, 77-91.	3.1	62
210	No evidence that protein truncating variants in <i>BRIP1</i> are associated with breast cancer risk: implications for gene panel testing. Journal of Medical Genetics, 2016, 53, 298-309.	3.2	94
211	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	21.4	125
212	Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer. Clinical Cancer Research, 2016, 22, 2583-2593.	7.0	289
213	Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium. Human Genetics, 2016, 135, 137-154.	3.8	8
214	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. Journal of the National Cancer Institute, 2016, 108, djv315.	6.3	77
215	Evidence of a genetic link between endometriosis and ovarian cancer. Fertility and Sterility, 2016, 105, 35-43.e10.	1.0	37
216	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	1.4	18

#	Article	IF	CITATIONS
217	RAD51B in Familial Breast Cancer. PLoS ONE, 2016, 11, e0153788.	2.5	26
218	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget, 2016, 7, 69097-69110.	1.8	5
219	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. Oncotarget, 2016, 7, 72381-72394.	1.8	13
220	Investigation of geneâ€environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors. International Journal of Cancer, 2015, 136, E685-96.	5.1	34
221	Endometriosis as a risk factor for ovarian or endometrial cancer — results of a hospital-based case–control study. BMC Cancer, 2015, 15, 751.	2.6	25
222	Epithelialâ€Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genetic Epidemiology, 2015, 39, 689-697.	1.3	22
223	Common germline polymorphisms associated with breast cancer-specific survival. Breast Cancer Research, 2015, 17, 58.	5.0	26
224	A comprehensive evaluation of interaction between genetic variants and use of menopausal hormone therapy on mammographic density. Breast Cancer Research, 2015, 17, 110.	5.0	19
225	Genetic variants in <scp>VEGF</scp> pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III <scp>G</scp> epar <scp>Q</scp> uinto study. International Journal of Cancer, 2015, 137, 2981-2988.	5.1	31
226	Association of molecular subtypes with breast cancer risk factors. European Journal of Cancer Prevention, 2015, 24, 484-490.	1.3	14
227	Large-Scale Genomic Analyses Link Reproductive Aging to Hypothalamic Signaling, Breast Cancer Susceptibility, and BRCA1-Mediated DNA Repair. Obstetrical and Gynecological Survey, 2015, 70, 758-762.	0.4	0
228	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. PLoS ONE, 2015, 10, e0128106.	2.5	44
229	Inhibition of Adhesion, Proliferation, and Invasion of Primary Endometriosis and Endometrial Stromal and Ovarian Carcinoma Cells by a Nonhyaluronan Adhesion Barrier Gel. BioMed Research International, 2015, 2015, 1-10.	1.9	7
230	SNP-SNP interaction analysis of NF-ήB signaling pathway on breast cancer survival. Oncotarget, 2015, 6, 37979-37994.	1.8	20
231	Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants. Journal of the National Cancer Institute, 2015, 107, .	6.3	428
232	Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. Human Molecular Genetics, 2015, 24, 3595-3607.	2.9	40
233	Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer. Journal of Clinical Oncology, 2015, 33, 304-311.	1.6	521
234	Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. Human Molecular Genetics, 2015, 24, 2966-2984.	2.9	40

#	Article	IF	CITATIONS
235	Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1. American Journal of Human Genetics, 2015, 96, 5-20.	6.2	76
236	Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer. Carcinogenesis, 2015, 36, 256-271.	2.8	14
237	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	21.4	221
238	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nature Genetics, 2015, 47, 373-380.	21.4	513
239	The Contributions of Breast Density and Common Genetic Variation to Breast Cancer Risk. Journal of the National Cancer Institute, 2015, 107, .	6.3	174
240	14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts. Breast Care, 2015, 10, 211-219.	1.4	43
241	Network-Based Integration of GWAS and Gene Expression Identifies a <i>HOX</i> -Centric Network Associated with Serous Ovarian Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1574-1584.	2.5	28
242	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. Clinical Cancer Research, 2015, 21, 5264-5276.	7.0	33
243	Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. American Journal of Human Genetics, 2015, 97, 22-34.	6.2	37
244	Identification of Novel Genetic Markers of Breast Cancer Survival. Journal of the National Cancer Institute, 2015, 107, .	6.3	56
245	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Gynecologic Oncology, 2015, 136, 542-548.	1.4	15
246	Candidate locus analysis of the TERT–CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk. Human Genetics, 2015, 134, 231-245.	3.8	34
247	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy. Breast Cancer Research, 2015, 17, 18.	5.0	20
248	Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures. Cancer Research, 2015, 75, 2457-2467.	0.9	55
249	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nature Communications, 2015, 6, 8234.	12.8	63
250	Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. Nature Genetics, 2015, 47, 1294-1303.	21.4	357
251	Common variants at the <i>CHEK2</i> gene locus and risk of epithelial ovarian cancer. Carcinogenesis, 2015, 36, 1341-1353.	2.8	24
252	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. Human Molecular Genetics, 2015, 24, 5955-5964.	2.9	68

#	Article	IF	CITATIONS
253	Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. Journal of the National Cancer Institute, 2015, 107, djv219.	6.3	99
254	Comprehensive genetic assessment of the ESR1 locus identifies a risk region for endometrial cancer. Endocrine-Related Cancer, 2015, 22, 851-861.	3.1	25
255	Fine-Scale Mapping of the 4q24 Locus Identifies Two Independent Loci Associated with Breast Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1680-1691.	2.5	24
256	Population Distribution of Lifetime Risk of Ovarian Cancer in the United States. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 671-676.	2.5	82
257	Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. Human Molecular Genetics, 2015, 24, 285-298.	2.9	38
258	Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. Human Molecular Genetics, 2015, 24, 1478-1492.	2.9	50
259	The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients. Oncotarget, 2015, 6, 7390-7407.	1.8	15
260	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). Journal of Genetics and Genome Research, 2015, 2, .	0.3	25
261	MicroRNA Related Polymorphisms and Breast Cancer Risk. PLoS ONE, 2014, 9, e109973.	2.5	49
262	Biomarkers in Women's Cancers, Gynecology, and Obstetrics. BioMed Research International, 2014, 2014, 1-2.	1.9	2
263	Circulating miR-148b and miR-133a as biomarkers for breast cancer detection. Oncotarget, 2014, 5, 5284-5294.	1.8	74
264	Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast. PLoS Genetics, 2014, 10, e1004285.	3.5	39
265	Meconium Indicators of Maternal Alcohol Abuse during Pregnancy and Association with Patient Characteristics. BioMed Research International, 2014, 2014, 1-11.	1.9	27
266	Variation in NF-κB Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1421-1427.	2.5	13
267	2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy. Nature Communications, 2014, 5, 4051.	12.8	16
268	Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. Human Molecular Genetics, 2014, 23, 6096-6111.	2.9	53
269	Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Research, 2014, 16, 3419.	5.0	97
270	Risk of Ovarian Cancer and the NF-κB Pathway: Genetic Association with <i>IL1A</i> and <i>TNFSF10</i> . Cancer Research, 2014, 74, 852-861.	0.9	48

#	Article	IF	CITATIONS
271	Large-Scale Evaluation of Common Variation in Regulatory T Cell–Related Genes and Ovarian Cancer Outcome. Cancer Immunology Research, 2014, 2, 332-340.	3.4	21
272	DNA mismatch repair gene MSH6 implicated in determining age at natural menopause. Human Molecular Genetics, 2014, 23, 2490-2497.	2.9	56
273	Polymorphisms in the <i>RANK/RANKL</i> Genes and Their Effect on Bone Specific Prognosis in Breast Cancer Patients. BioMed Research International, 2014, 2014, 1-7.	1.9	18
274	<i>CYP2B6</i> *6 is associated with increased breast cancer risk. International Journal of Cancer, 2014, 134, 426-430.	5.1	24
275	Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet, The, 2014, 384, 164-172.	13.7	3,224
276	A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46 450 cases and 42 461 controls from the breast cancer association consortium. Human Molecular Genetics, 2014, 23, 1934-1946.	2.9	32
277	Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma. Breast Cancer Research and Treatment, 2014, 144, 153-162.	2.5	92
278	Comprehensive visualization of paresthesia in breast cancer survivors. Archives of Gynecology and Obstetrics, 2014, 290, 135-141.	1.7	11
279	Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Human Genetics, 2014, 133, 481-497.	3.8	23
280	HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics. Breast Cancer Research and Treatment, 2014, 145, 193-203.	2.5	31
281	Identification of New Genetic Susceptibility Loci for Breast Cancer Through Consideration of Geneâ€Environment Interactions. Genetic Epidemiology, 2014, 38, 84-93.	1.3	28
282	Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. Carcinogenesis, 2014, 35, 1012-1019.	2.8	145
283	Genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk. Nature Communications, 2014, 5, 5303.	12.8	109
284	Consortium analysis of gene and gene–folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. Molecular Nutrition and Food Research, 2014, 58, 2023-2035.	3.3	16
285	Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. Nature, 2014, 514, 92-97.	27.8	548
286	<i>PIK3CA</i> Mutations Are Associated With Lower Rates of Pathologic Complete Response to Anti–Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer. Journal of Clinical Oncology, 2014, 32, 3212-3220.	1.6	231
287	Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial. Breast Cancer Research and Treatment, 2014, 147, 61-68.	2.5	108
288	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. Nature Communications, 2014, 5, 4999.	12.8	105

#	Article	IF	CITATIONS
289	Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. Human Molecular Genetics, 2014, 23, 6034-6046.	2.9	12
290	Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncology, The, 2014, 15, 747-756.	10.7	810
291	Molecular profiling of single circulating tumor cells with diagnostic intention. EMBO Molecular Medicine, 2014, 6, 1371-1386.	6.9	218
292	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. Breast Cancer Research, 2014, 16, R51.	5.0	14
293	HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer. Breast Cancer Research, 2013, 15, R11.	5.0	59
294	ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecologic Oncology, 2013, 131, 8-14.	1.4	55
295	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature Genetics, 2013, 45, 362-370.	21.4	326
296	Fine-Scale Mapping of the FGFR2 Breast Cancer Risk Locus: Putative Functional Variants Differentially Bind FOXA1 and E2F1. American Journal of Human Genetics, 2013, 93, 1046-1060.	6.2	98
297	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	21.4	493
298	Prognostic molecular markers and neoadjuvant therapy response in anthracycline-treated breast cancer patients. Archives of Gynecology and Obstetrics, 2013, 287, 337-344.	1.7	13
299	Functional Variants at the 11q13 Risk Locus for Breast Cancer Regulate Cyclin D1 Expression through Long-Range Enhancers. American Journal of Human Genetics, 2013, 92, 489-503.	6.2	201
300	Genome-wide association studies identify four ER negative–specific breast cancer risk loci. Nature Genetics, 2013, 45, 392-398.	21.4	374
301	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nature Genetics, 2013, 45, 353-361.	21.4	960
302	Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC)±bevacizumab – Results of the randomised GeparQuinto study (GBG 44). European Journal of Cancer, 2013, 49, 2284-2293.	2.8	75
303	Polymorphisms in Inflammation Pathway Genes and Endometrial Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 216-223.	2.5	22
304	Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk. PLoS Genetics, 2013, 9, e1003173.	3.5	105
305	Evidence of Gene–Environment Interactions between Common Breast Cancer Susceptibility Loci and Established Environmental Risk Factors. PLoS Genetics, 2013, 9, e1003284.	3.5	136
306	Hormone replacement therapy and prognosis in ovarian cancer patients. European Journal of Cancer Prevention, 2013, 22, 52-58.	1.3	28

#	Article	IF	CITATIONS
307	Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer. Clinical Cancer Research, 2013, 19, 4521-4531.	7.0	137
308	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nature Communications, 2013, 4, 1628.	12.8	144
309	Analysis of Over 10,000 Cases Finds No Association between Previously Reported Candidate Polymorphisms and Ovarian Cancer Outcome. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 987-992.	2.5	20
310	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nature Communications, 2013, 4, 1627.	12.8	98
311	The UGT1A6_19_GG genotype is a breast cancer risk factor. Frontiers in Genetics, 2013, 4, 104.	2.3	8
312	Common Breast Cancer Susceptibility Variants in <i>LSP1</i> and <i>RAD51L1</i> Are Associated with Mammographic Density Measures that Predict Breast Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1156-1166.	2.5	101
313	19p13.1 Is a Triple-Negative–Specific Breast Cancer Susceptibility Locus. Cancer Research, 2012, 72, 1795-1803.	0.9	100
314	Circulating Micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection. PLoS ONE, 2012, 7, e29770.	2.5	219
315	<i>CHEK2</i> *1100delC Heterozygosity in Women With Breast Cancer Associated With Early Death, Breast Cancer–Specific Death, and Increased Risk of a Second Breast Cancer. Journal of Clinical Oncology, 2012, 30, 4308-4316.	1.6	162
316	The role of genetic breast cancer susceptibility variants as prognostic factors. Human Molecular Genetics, 2012, 21, 3926-3939.	2.9	80
317	Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncology, The, 2012, 13, 135-144.	10.7	425
318	Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies. Lancet Oncology, The, 2012, 13, 385-394.	10.7	753
319	Characterizing mammographic images by using generic texture features. Breast Cancer Research, 2012, 14, R59.	5.0	65
320	Association of mammographic density with the proliferation marker Ki-67 in a cohort of patients with invasive breast cancer. Breast Cancer Research and Treatment, 2012, 135, 885-892.	2.5	36
321	Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nature Genetics, 2012, 44, 312-318.	21.4	256
322	Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer. New England Journal of Medicine, 2012, 366, 299-309.	27.0	473
323	9q31.2-rs865686 as a Susceptibility Locus for Estrogen Receptor-Positive Breast Cancer: Evidence from the Breast Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1783-1791.	2.5	17
324	Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes. Journal of Clinical Oncology, 2012, 30, 1796-1804.	1.6	2,062

#	Article	IF	CITATIONS
325	A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Human Molecular Genetics, 2012, 21, 5373-5384.	2.9	168
326	11q13 is a susceptibility locus for hormone receptor positive breast cancer. Human Mutation, 2012, 33, 1123-1132.	2.5	35
327	Association of mammographic density with hormone receptors in invasive breast cancers: Results from a caseâ€only study. International Journal of Cancer, 2012, 131, 2643-2649.	5.1	44
328	Genome-Wide Association Study Identifies a Possible Susceptibility Locus for Endometrial Cancer. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 980-987.	2.5	32
329	Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). PLoS ONE, 2012, 7, e42380.	2.5	51
330	Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptor–Positive, Lower Grade Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2222-2231.	2.5	27
331	Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies. Journal of the National Cancer Institute, 2011, 103, 250-263.	6.3	596
332	Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Human Molecular Genetics, 2011, 20, 3289-3303.	2.9	152
333	A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor–negative breast cancer. Nature Genetics, 2011, 43, 1210-1214.	21.4	279
334	Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer, 2011, 11, 486.	2.6	260
335	Mammographic density as a risk factor for breast cancer in a German case–control study. European Journal of Cancer Prevention, 2011, 20, 1-8.	1.3	53
336	Re-Challenging Taxanes in Recurrent Breast Cancer in Patients Treated with (Neo-)Adjuvant Taxane-Based Therapy. Breast Care, 2011, 6, 279-283.	1.4	14
337	Genome-wide association study identifies a common variant associated with risk of endometrial cancer. Nature Genetics, 2011, 43, 451-454.	21.4	141
338	Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Research and Treatment, 2011, 125, 145-156.	2.5	228
339	Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. International Journal of Cancer, 2011, 128, 2063-2074.	5.1	54
340	Assessment of Hepatocyte Growth Factor in Ovarian Cancer Mortality. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1638-1648.	2.5	31
341	Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortiumâ€. Human Molecular Genetics, 2011, 20, 4693-4706.	2.9	71
342	The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing. Clinical Cancer Research, 2011, 17, 3742-3750.	7.0	47

#	Article	IF	CITATIONS
343	Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups. Journal of Clinical Oncology, 2011, 29, 3351-3357.	1.6	456
344	Common Breast Cancer Susceptibility Loci Are Associated with Triple-Negative Breast Cancer. Cancer Research, 2011, 71, 6240-6249.	0.9	109
345	Estrogen Receptor Beta rs1271572 Polymorphism and Invasive Ovarian Carcinoma Risk: Pooled Analysis within the Ovarian Cancer Association Consortium. PLoS ONE, 2011, 6, e20703.	2.5	21
346	Assessment of mammographic density before and after first full-term pregnancy. European Journal of Cancer Prevention, 2010, 19, 405-412.	1.3	21
347	Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study. Breast Cancer Research, 2010, 12, R110.	5.0	82
348	Pain perception and detailed visual pain mapping in breast cancer survivors. Breast Cancer Research and Treatment, 2010, 119, 105-110.	2.5	24
349	Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nature Genetics, 2010, 42, 880-884.	21.4	235
350	A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nature Genetics, 2010, 42, 874-879.	21.4	321
351	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general population. Nature Genetics, 2010, 42, 885-892.	21.4	309
352	Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study. Journal of Clinical Oncology, 2010, 28, 2024-2031.	1.6	487
353	Capecitabine in Addition to Anthracycline- and Taxane-Based Neoadjuvant Treatment in Patients With Primary Breast Cancer: Phase III GeparQuattro Study. Journal of Clinical Oncology, 2010, 28, 2015-2023.	1.6	194
354	<i>CYP2D6</i> Polymorphisms as Predictors of Outcome in Breast Cancer Patients Treated with Tamoxifen: Expanded Polymorphism Coverage Improves Risk Stratification. Clinical Cancer Research, 2010, 16, 4468-4477.	7.0	81
355	Association Between a Germline OCA2 Polymorphism at Chromosome 15q13.1 and Estrogen Receptor–Negative Breast Cancer Survival. Journal of the National Cancer Institute, 2010, 102, 650-662.	6.3	48
356	Nachsorge mit Rezidiv- und Metastasensuche und Therapiebegleitung. , 2010, , 262-269.		0
357	Association of ESR1 gene tagging SNPs with breast cancer risk. Human Molecular Genetics, 2009, 18, 1131-1139.	2.9	84
358	Risk of Estrogen Receptor–Positive and –Negative Breast Cancer and Single–Nucleotide Polymorphism 2q35-rs13387042. Journal of the National Cancer Institute, 2009, 101, 1012-1018.	6.3	99
359	Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients. Breast, 2009, 18, 135-141.	2.2	76
360	A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nature Genetics, 2009, 41, 996-1000.	21.4	276

#	Article	IF	CITATION
361	Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen. JAMA - Journal of the American Medical Association, 2009, 302, 1429.	7.4	468
362	Early aberrant insulinâ€like growth factor signaling in the progression to endometrial carcinoma is augmented by tamoxifen. International Journal of Cancer, 2008, 123, 2871-2879.	5.1	37
363	Correlates of the desire for improved cosmetic results after breast-conserving therapy and mastectomy in breast cancer patients. Breast, 2008, 17, 640-645.	2.2	16
364	Evaluation of mathematical models for breast cancer risk assessment in routine clinical use. European Journal of Cancer Prevention, 2007, 16, 216-224.	1.3	27
365	Lymphedema in breast cancer survivors: Assessment and information provision in a specialized breast unit. Patient Education and Counseling, 2007, 66, 311-318.	2.2	65
366	Hereditary breast and ovarian cancer: review and future perspectives. Journal of Molecular Medicine, 2006, 84, 16-28.	3.9	149
367	Proliferation and cell–cell fusion of endometrial carcinoma are induced by the human endogenous retroviral Syncytin-1 and regulated by TGF-Î2 Journal of Molecular Medicine, 2006, 85, 23-38	3.9	132